Christopher Walker

Christopher Walker is a distinguished cancer geneticist and the Director of Bioinformatics at Karyopharm Therapeutics Inc., where he plays a pivotal role in advancing the development of novel cancer therapeutics through innovative biomarker discovery. With a robust background in molecular biology and substantial expertise in bioinformatics, Christopher leads a dynamic team that integrates cutting-edge genomic and epigenomic analyses into clinical evaluations. His work is instrumental in bridging the gap between laboratory discoveries and clinical applications, ensuring that promising biomarkers are effectively translated into actionable insights for patient treatment.

At Karyopharm, Christopher oversees the analysis of both public and proprietary datasets, conducting correlative studies that are critical for identifying and validating biomarkers that can predict treatment responses. His leadership in maintaining and optimizing high-throughput next-generation sequencing (NGS) pipelines is vital for processing complex genomic data, enabling the team to derive meaningful conclusions that inform therapeutic strategies. His collaborative approach involves working closely with interdisciplinary teams, including preclinical researchers, clinical oncologists, and regulatory experts, to ensure that biomarker discoveries align with clinical objectives and regulatory standards.

Christopher's academic journey has been shaped by mentorship from some of the most respected figures in genetics and oncology, equipping him with a unique perspective on the molecular prognostication of diseases like leukemia. His expertise encompasses a wide range of skills, including laboratory techniques such as Western blotting and enzyme assays, as well as advanced statistical analyses and study design. As a thought leader in the field, Christopher is committed to leveraging his knowledge and experience to drive forward the mission of Karyopharm Therapeutics, ultimately improving outcomes for patients battling cancer.